Premium
Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia
Author(s) -
Kuss Bryone J.,
Tam Constantine S.
Publication year - 2017
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.13680
Subject(s) - ibrutinib , venetoclax , medicine , idelalisib , chemoimmunotherapy , chronic lymphocytic leukemia , oncology , rituximab , alemtuzumab , asymptomatic , leukemia , lymphoma , transplantation
Abstract Background Chronic lymphocytic leukaemia (CLL) frequently responds to chemoimmunotherapy combining cytotoxic chemotherapy and monoclonal antibodies. However, CLL is associated with significant genetic heterogeneity, and some high‐risk forms are known to be chemo‐resistant and associated with early relapse. Aims To review the current treatment paradigm of patients with high‐risk disease, in particular those with del(17p) and TP53 variants. Results A ‘watch and wait’ approach is recommended for all patients who are asymptomatic. When symptomatic, fluorescence in situ hybridisation testing should be performed and gene sequencing considered subsequently to identify del(17p) and TP53 variants respectively. In the front‐line setting, treatment within a clinical trial is the preferred option. In the relapsed or refractory setting, patients with del(17p) or TP53 aberrations should be offered treatment with a novel agent, such as ibrutinib, idelalisib‐rituximab or venetoclax. However, of note, at the date of this publication venetoclax is not PBS reimbursed, and ibrutinib will not be reimbursed until 1 December 2017. Conclusion Testing for del(17p) and TP53 variants identifies high‐risk CLL that requires specialist management.